naltrexone and Multiple Sclerosis

naltrexone has been researched along with Multiple Sclerosis in 19 studies

Research

Studies (19)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (21.05)	29.6817
2010's	12 (63.16)	24.3611
2020's	3 (15.79)	2.80

Authors

Authors	Studies
Arnett, PA; McLaughlin, PJ; Odom, LB; Orehek, S; Thomas, GA; Zagon, IS	1
Fishman, MA; Kim, PS	1
Barrientos, RM; Clements, MA; Duran-Malle, JC; Harris, KM; Kwilasz, AJ; Larson, TA; Litwiler, ST; Maier, SF; Mitten, EH; Rice, KC; Schrama, AEW; Todd, LS; Van Dam, AM; Wang, X; Watkins, LR	1
Ludwig, MD; McLaughlin, PJ; Zagon, IS	2
Raknes, G; Småbrekke, L	1
Berlau, DJ; Patten, DK; Schultz, BG	1
Feng, J; Griffin, N; Li, Z; Shan, F; You, Y	1
McLaughlin, PJ; Zagon, IS	1
Hammer, LA; McLaughlin, PJ; Waldner, H; Zagon, IS	1
McLaughlin, PJ; Oh, KH; Turel, AP; Zagon, IS	1
Handberg, G; Plesner, KB; Vægter, HB	1
McLaughlin, PJ; Rahn, KA; Turel, AP; Zagon, IS	1
Cree, BA; Goodin, DS; Kornyeyeva, E	1
Giverhaug, T; Raknes, G	1
Holmøy, T	1
Agrawal, YP	1
Good, P	1
Patel, PN	1

Reviews

5 review(s) available for naltrexone and Multiple Sclerosis

Article	Year
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review. Current pain and headache reports, 2020, Aug-26, Volume: 24, Issue:10 Topics: Chronic Pain; Fibromyalgia; Humans; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders	2020
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders. Pharmacotherapy, 2018, Volume: 38, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Chronic Pain; Crohn Disease; Dose-Response Relationship, Drug; Fibromyalgia; Humans; Inflammation; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Quality of Life	2018
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. International immunopharmacology, 2018, Volume: 61 Topics: Analgesics, Opioid; Animals; Autoimmunity; Crohn Disease; Drug Dosage Calculations; Humans; Immunologic Factors; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Neoplasms; Off-Label Use; Receptors, Opioid; Substance Abuse Treatment Centers	2018
Intermittent blockade of OGFr and treatment of autoimmune disorders. Experimental biology and medicine (Maywood, N.J.), 2018, Volume: 243, Issue:17-18 Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Humans; Mice; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Receptors, Opioid	2018
[Low dose naltrexone for treatment of pain]. Ugeskrift for laeger, 2015, Oct-09, Volume: 177, Issue:43 Topics: Analgesics, Opioid; Crohn Disease; Fibromyalgia; Humans; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Pain	2015

Trials

1 trial(s) available for naltrexone and Multiple Sclerosis

Article	Year
Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:2 Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Mood Disorders; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Pilot Projects; Placebos; Quality of Life; Young Adult	2010

Other Studies

13 other study(ies) available for naltrexone and Multiple Sclerosis

Article	Year
Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic. International immunopharmacology, 2022, Volume: 113, Issue:Pt B Topics: Anxiety; COVID-19 Drug Treatment; Humans; Multiple Sclerosis; Naltrexone; Pandemics	2022
Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone. Behavioural brain research, 2021, 01-01, Volume: 396 Topics: Animals; Behavior, Animal; Cells, Cultured; Conditioning, Classical; Encephalomyelitis, Autoimmune, Experimental; Fear; Hippocampus; Inflammation; Male; Memory Disorders; Mice; Microglia; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Toll-Like Receptor 2; Toll-Like Receptor 4	2021
Featured Article: Serum [Met Experimental biology and medicine (Maywood, N.J.), 2017, Volume: 242, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Animals; Biomarkers; Encephalomyelitis, Autoimmune, Experimental; Enkephalin, Methionine; Female; Humans; Male; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis; Naltrexone; Neuroprotective Agents; Serum; Treatment Outcome; Volunteers; Young Adult	2017
Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study. PloS one, 2017, Volume: 12, Issue:11 Topics: Dose-Response Relationship, Drug; Humans; Multiple Sclerosis; Naltrexone; Norway	2017
Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis. Experimental biology and medicine (Maywood, N.J.), 2018, Volume: 243, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Animals; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Enkephalin, Methionine; Female; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis; Naltrexone; Receptors, Opioid	2018
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis. Experimental biology and medicine (Maywood, N.J.), 2016, Volume: 241, Issue:1 Topics: Animals; CD4-Positive T-Lymphocytes; Central Nervous System; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enkephalin, Methionine; Female; Mice; Multiple Sclerosis; Naltrexone; Narcotic Antagonists	2016
Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:5 Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Retrospective Studies; Treatment Outcome; Young Adult	2015
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Experimental biology and medicine (Maywood, N.J.), 2009, Volume: 234, Issue:11 Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Naltrexone; Nervous System	2009
[Naltrexone--high expectations to low dosages]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, May-06, Volume: 131, Issue:8 Topics: Crohn Disease; Dose-Response Relationship, Drug; Humans; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Treatment Outcome	2011
[Research on low dosage naltrexone]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, Jul-01, Volume: 131, Issue:13-14 Topics: Dose-Response Relationship, Drug; Humans; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Research Support as Topic	2011
Low dose naltrexone therapy in multiple sclerosis. Medical hypotheses, 2005, Volume: 64, Issue:4 Topics: Apoptosis; Dose-Response Relationship, Drug; Humans; Multiple Sclerosis; Naltrexone; Oxidative Stress	2005
Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause? Medical hypotheses, 2006, Volume: 67, Issue:3 Topics: Anti-Inflammatory Agents; Autistic Disorder; Dose-Response Relationship, Drug; Humans; Models, Biological; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Nitric Oxide Synthase Type II	2006
Low-dose naltrexone for treatment of multiple sclerosis: clinical trials are needed. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:9 Topics: Clinical Trials as Topic; Humans; Multiple Sclerosis; Naltrexone; Narcotic Antagonists	2007